For more than four decades, Lilly Oncology has been dedicated to delivering innovative treatment approaches with the goal of improving the outcomes of people living with cancer. We are driven to accelerate the pace and progress of cancer care by developing a portfolio of tailored therapies as vast and unique as the patients themselves. ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, echoes our commitment to advancing oncology care through targeted biologic treatments designed to address the medical needs of patients with a variety of cancers.